Clinical trial NCT02630979: Oncologists Satisfaction With Outcomes of Some Cytotoxic Agents
Official title: Prospective Observational Questionnaire Based Study Measuring Oncology Physicians Knowledge and Satisfaction With the Outcomes of Expensive Cytotoxic Agents
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Physician Satisfaction With the Outcomes of Cytotoxic Drugs
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2015-12-15
Enrollment: 150
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Medical or clinical oncology doctors

Brief summary: The study measures the degree of oncology physician satisfaction with the outcomes of some cytotoxic agents.

Detailed description: This is a prospective observational questionnaire based study measuring the degree of satisfaction of medical oncologists with the results of some expensive cytotoxic agents. The study also measures the physician knowledge with the toxicity profile of the tested drugs, pharmaceutical perspectives, methods of administration, adherence to guidelines and the degree of bias of the physicians when prescribing this drugs.

The tested drugs are trastuzumab, lapatinib, sunitinib, m tor inhibitors, sorafenib, cetuximab, panitumumab, bevacizumab, erlotinib, rituximab, imatinib mesylate, gefitinib, abiraterone acetate, cabazitaxel, pertuzumab, fulvestrant, pemetrexate and crizotinib.

The evaluation will be through a predesigned questionnaire ( 30 questions ). The questions are divided into four categories measuring four items, the degree of physician satisfaction with the drugs results and toxicity profile, orientation with pharmaceutical perspectives of the drugs, adherence to guidelines and degree of bias with pharmaceutical companies complements. A predesigned questionnaire based scoring system will categorise the processed data to low, intermediate and high score for each of the four measured topics. The data will be processed and the degree of satisfaction, orientation with pharmaceutical perspectives, adherence to guidelines and degree of bias will be grade to low, moderate or high. Subsequent recommendations for cost effective analysis, physician education and strict auditing measures for drug prescription will be elaborated for the drugs.

NB: The study will be on two waves. The first wave will evaluate 9 drugs and the second wave will evaluate 8 drugs.

Eligibility criteria: Inclusion Criteria:

* Physicians ranked from senior resident to professional consultants

Exclusion Criteria:

* Junior residents.

Primary outcomes:
measure: Questionnaire based measurement of the degree of physician satisfaction with the results and toxicity of some cytotoxic drugs.
timeFrame: One year
measure: Questionnaire based measurement of the degree of physician orientation with pharmaceutical perspectives of some cytotoxic drugs.
timeFrame: One year
measure: Questionnaire based measurement of the degree of physician adherence to guidelines in prescribing some cytotoxic drugs.
timeFrame: One year
measure: Questionnaire based measurement of the degree of physician bias while prescribing some cytotoxic drugs.
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Faculty of Medicine. AIn Shams University
state: Elabbasia
Study officials:
affiliation: Faculty of Medicine. Ain Shams University
name: Mahmoud Ellithy, Consultant
role: PRINCIPAL_INVESTIGATOR
affiliation: Misr university
name: Noha Salaheldin elbogdady, Pharmaciest
role: STUDY_DIRECTOR
References: